Margaret McLoughlin, Director at Quince Therapeutics, Inc. (QNCX), bought 8,000 shares at $1.23 ($10K) on 2023-08-08, disclosed to the SEC on 2023-08-09.
Open-market purchase of $10k QNCX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| CRTX | SELL | 2021-06-29 | $30K | — | Filing → |
| CRTX | BUY | 2020-03-12 | $9K | — | Filing → |